A5078818396- Psoriasis: Treatment and Pathogenesis
- Autoimmune Bullous Skin Diseases
- Dermatology and Skin Diseases
- Pharmaceutical studies and practices
- Health Systems, Economic Evaluations, Quality of Life
- Autoimmune and Inflammatory Disorders
- Nail Diseases and Treatments
- Skin Diseases and Diabetes
- Parvovirus B19 Infection Studies
- Cancer and Skin Lesions
- Mast cells and histamine
- Asthma and respiratory diseases
- Chemotherapy-related skin toxicity
- Antifungal resistance and susceptibility
- Cancer Treatment and Pharmacology
- Spondyloarthritis Studies and Treatments
- Cytokine Signaling Pathways and Interactions
- Eosinophilic Disorders and Syndromes
- Cutaneous lymphoproliferative disorders research
- Dermatological and COVID-19 studies
- Rheumatoid Arthritis Research and Therapies
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Inflammatory Bowel Disease
- Histiocytic Disorders and Treatments
- Polyomavirus and related diseases
Hospital General Universitario Gregorio Marañón
2015-2024
Universidad Complutense de Madrid
2020-2021
Hospital Universitario 12 De Octubre
2020
Hospital General Universitario de Alicante Doctor Balmis
2020
Hospital Clínico Universitario Virgen de la Victoria
2020
Hospital Universitario Insular de Gran Canaria
2020
Hospital Universitario Infanta Leonor
2020
Hospital Universitario de La Princesa
2020
Hospital Universitario Reina Sofía
2020
Hospital Universitario Ramón y Cajal
2003-2005
The cutaneous manifestations of COVID-19 disease are poorly characterized.To describe the and to relate them other clinical findings.We carried out a nationwide case collection survey images data. Using consensus we described five patterns. We later association these patterns with patient demographics, timing in relation symptoms disease, severity prognosis.The lesions may be classified as acral areas erythema vesicles or pustules (pseudo-chilblain) (19%), vesicular eruptions (9%),...
A previous study has defined the maculopapular subtype of manifestations COVID-19. The objective our was to describe and classify eruptions associated with COVI-19. We carried out a subanalysis cases found in cross-sectional study. Using consensus, we seven clinical patterns. described patient demographics, therapy received by characteristics each pattern. Consensus lead description major patterns: morbilliform (45.5%), other (20.0%), purpuric (14.2%), erythema multiforme-like (9.7%),...
Psoriasis improves when IL-17 is blocked. Anti-TNF drugs reduce the signaling pathway, and anti-IL-17 are being developed to treat moderate-to-severe psoriasis. We analyzed three SNPs in IL-17A (rs2275913 rs10484879) IL-17F (rs763780) look for an association with psoriasis and/or response anti-TNF or ustekinumab. included 197 healthy controls 194 patients The results of univariate analysis showed between rs10484879 psoriasis, although this relationship disappeared after adjustment HLA-C...
The treatment of cutaneous lupus erythematosus (CLE) with dye and argon laser has been evaluated in a number articles recent years. improvement telangiectasias chronic erythema the lesions was based on selective photothermolysis ablation dilated capillaries venules.We describe results 14 patients; eight discoid (DLE) six systemic (SLE). Three patients received flashlamp pulsed (FPDL) (585 nm, 450 microseconds) fluences range from 5 to 7.75 J/cm(2); other 11 were treated long (LPDL) (595...
In biologic therapy, dose modification in carefully selected patients when psoriasis is remission could reduce treatment costs and the risks associated with drug exposure. Observational, descriptive, cross-sectional study, performed January 2014, of 112 moderate to severe who had been on therapy for at least 6 months. The therapeutic objective all cases was achieve maintain a 75% reduction Psoriasis Area Severity Index (PASI 75). All started standard regimen. During treatment, reduced...
The effect of sex on systemic therapy for psoriasis has not been well studied. aim this study was to analyse a large multicentre Spanish cohort 2,881 patients with (58.3% males), followed from January 2008 November 2018, determine whether influences prescription, effectiveness therapy, and the risk adverse events. results show that women are more likely than men be prescribed biologics. There were no differences between in measured terms drug survival. Women develop events, but difference...
There is limited and conflicting evidence over the real-world drug survival of secukinumab (SEC) in patients with psoriasis, especially long term. Our objective was to analyze short- long-term SEC (S-SEC) its predictive factors for treatment psoriasis. Patients clinically diagnosed plaque psoriasis under (n = 384) a daily practice setting were analyzed retrospective, multicenter study performed nationwide cohort followed up period 2 years. Kaplan-Meier curve plotted time, log-rank test...
Psoriasis is a chronic skin disease in which genetics play major role. Although many genome-wide association studies have been performed psoriasis, knowledge of the age at onset remains limited. Therefore, we analyzed 173 single-nucleotide polymorphisms genes associated with psoriasis and other autoimmune diseases patients moderate-to-severe plaque type I (early-onset, <40 years) or II (late-onset, ≥40 healthy controls. Moreover, comparison between psoriasis. Our stratified population (n =...
Biological therapy dose modification is a common practice in the long-term treatment of plaque psoriasis.
Abstract Detecting the association of genetic variants to response biological therapy represents an important advance in developing a personalized therapy. The aim this work was study polymorphisms with optimal tildrakizumab patients psoriasis real‐life clinical practice. Ninety plaque recruited from—Spanish hospitals receiving for at least 24 weeks were genotyped 180 polymorphisms. Optimal evaluated by absolute PASI ≤1 6 and 12 months. Polymorphisms corrected weight disease duration FDR...
Abstract Background Safety is an important consideration in decisions on treatment for patients with moderate-to-severe psoriasis and the study of drug safety main purpose BIOBADADERM registry. The combination a biologic agent conventional systemic [generally methotrexate (MTX)] common clinical practice. However, there paucity evidence from real-world practice such regimens psoriasis. Objectives primary objective this was to ascertain whether use combining drugs MTX management increases risk...
<h3>Objectives</h3> Interleukin-17 (IL-17) contributes to the pathogenesis of psoriasis. Secukinumab, ixekizumab, and brodalumab are monoclonal antibodies anti-IL-17 antibodies, approved for treatment moderate/severe plaque The aim study was describe effectiveness safety agents in psoriasis clinical practice. We also analysed therapies' survival, dose adjustment, patients' factors associated with their safety. <h3>Methods</h3> A retrospective, longitudinal conducted at a tertiary hospital....